2015 Press Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
06/30/15AVEO Oncology Announces Additional Biomarker Analyses from BATON-CRC Tivozanib Study to be Presented at the ESMO 17th World Congress on Gastrointestinal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 30, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that additional biomarker analyses from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study will be presented at the European Society for Medical Oncology (ESMO) 17th World Congress on Gastrointestinal Cancer, taking place July 1-4 in Barcelona, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth facto... 
Printer Friendly Version
06/11/15AVEO Announces FDA Update for Tivozanib in Colorectal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 11, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors. ... 
Printer Friendly Version
06/03/15AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 3, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for tivozanib in Europe for the treatment of renal cell carcinoma (RCC), it has received written confirmation of support from the Rapporteur and co-Rapporteur for the filing of such an application. The Rapporteur (from Portugal) and... 
Printer Friendly Version
05/29/15AVEO Oncology to Present at Jefferies 2015 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 29, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 at 8:00 AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at www.aveooncology.com. A replay of the webcast ... 
Printer Friendly Version
05/26/15AVEO Oncology Announces New Corporate Headquarters in Cambridge, Massachusetts
Unveils New Corporate Logo CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 26, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the relocation of its corporate headquarters to One Broadway in Cambridge, Massachusetts, effective today. Consistent with the Company’s goal of streamlining operations to align with its needs going forward, the new facility consists of approximately 5,000 square feet of office space under flexible lease terms, with ... 
Printer Friendly Version
05/20/15AVEO Oncology Announces Presentation of Final Results of Extension Study 902 and FDA Regulatory Feedback for Advancing Tivozanib in Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2015-- AVEO Oncology (NASDAQ:AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease progression on sorafenib in the Company’s Phase 3 TIVO-1 first-line RCC study, will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meetin... 
Printer Friendly Version
05/07/15AVEO Oncology Reports First Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2015. “We continue to execute on our strategy of leveraging biomarker insights and exploring partnership opportunities to advance our pipeline, while continuing to streamline AVEO’s operations to align with our needs,” said Michael Bailey, president and chief executive officer. “In parallel, we... 
Printer Friendly Version
04/22/15AVEO Names Keith S. Ehrlich as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 22, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company’s financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report to Michael Bailey, AVEO’s president and chief executive officer. ... 
Printer Friendly Version
04/20/15AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 20, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. The data were presented in a poster titled “Effective treatment of cancer associated cachexia by AV-38... 
Printer Friendly Version
03/06/15AVEO Oncology Reports Full Year 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2014. “At the beginning of 2015, AVEO implemented several important changes designed to maximize the value of our portfolio of clinical stage products,” said Michael Bailey, president and chief executive officer. “Our approach to realizing this value is to leverage biomarker insights, including... 
Printer Friendly Version
03/06/15AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients with Advanced CRC
Results Presented at AACR Tumor Angiogenesis and Vascular Normalization Conference AVEO to Host Conference Call Today, March 6, 2015 at 8:00 am ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of... 
Printer Friendly Version
02/27/15AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker Analysis from Phase 2 Study of Tivozanib in Patients with Advanced Colorectal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call and webcast on Friday, March 6, 2015, at 8:00 a.m. Eastern Time to discuss the presentation of final results and a predefined biomarker analysis of its BATON-CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer. The presentation, titl... 
Printer Friendly Version
01/12/15AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 12, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at aveooncology.com. A replay of the webca... 
Printer Friendly Version
01/09/15AVEO Names Michael N. Needle, M.D., As Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company’s partnered and proprietary pipeline programs. He will report to Michael Bailey, AVEO’s president and ch... 
Printer Friendly Version
01/08/15AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency
Company to Evaluate Potential for Submission of a Tivozanib MAA for the Treatment of RCC CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency’s centralized procedure. Confirmation of eligibility was giv... 
Printer Friendly Version
01/07/15AVEO Announces Executive Transition and Corporate Restructuring
Michael P. Bailey Named President and Chief Executive Officer; Tuan Ha-Ngoc Named Chairman of the Board Company to Eliminate Internal Research Function to Align Corporate Resources with the Company’s Future Strategic Plans CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 7, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that its Board of Directors has appointed Michael P. Bailey as the Company’s president and chief executive officer and has... 
Printer Friendly Version